Barbara Ryan News
-
Eli Lilly & Co. sought to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s.
-
Sanofi, unlike rivals such as Merck & Co., won’t push hard to find an Alzheimer’s treatment because the science isn’t advanced enough to justify the costs to develop a drug, Chief Executive Officer Chris Viehbacher said.
-
Eli Lilly & Co. and AstraZeneca Plc won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug lost U.S. patent protection yesterday.
-
Eli Lilly & Co. and AstraZeneca Plc won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug lost U.S. patent protection yesterday.
-
Merck & Co. rose to its highest value in four years after the company said it will stop testing an experimental drug meant to prevent bone fractures in women with osteoporosis because the therapy worked so well in a trial.
-
Bristol-Myers Squibb Co. said second-quarter profit fell in line with analyst expectations, as sales of the company’s top-selling drug Plavix plunged 60 percent after losing market exclusivity in May.
-
Johnson & Johnson and Pfizer Inc.’s bapineuzumab, an experimental drug that failed to help Alzheimer’s symptoms in a study, showed signs of reducing physical damage in the brain, according to a deeper analysis.
-
Eli Lilly & Co. and AstraZeneca Plc won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection today.
-
Pfizer Inc., Johnson & Johnson and Elan Corp.’s experimental Alzheimer’s treatment failed to improve symptoms of dementia in the first of four pivotal studies testing the drug.
-
Bristol-Myers Squibb Co. ’s second- quarter earnings beat analysts’ estimates as the drugmaker reduced costs and boosted sales of the blood thinner Plavix and treatments for HIV and hepatitis.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page